Appointment highlights Cardiosense’s growth trajectory following FDA clearance, clinical milestones, and expanded leadership team
Cardiosense, a digital health company pioneering AI-enabled solutions for cardiac disease management, announced the appointment of Eric Meizlish as Chief Executive Officer (CEO). Meizlish, a seasoned healthcare technology executive with experience scaling innovative health platforms, will lead the company through its next phase of growth, succeeding co-founder Amit Gupta, who will continue as Chief Strategy Officer.
“Since co-founding the company, Amit has worked tirelessly to set the strategic vision and mission for Cardiosense, while achieving significant product and regulatory milestones, assembling a world-class team, and establishing a strong culture and foundation for continued growth,” said Jeff Trost, Managing Partner, Laerdal Million Lives Fund. “We want to thank Amit for his leadership, and we are excited to continue working together in his new role alongside Eric.”
“Eric’s appointment marks an important step in Cardiosense’s evolution as we scale our platform to democratize precision cardiac care,” said Daniel Gottlieb, Director, Broadview Ventures. “By delivering actionable insights without costly implantable sensors, the company is well-positioned to expand its impact, and Eric is the right leader to accelerate this momentum.”
Also Read: Sutter Health Partners with Hyro to Transform Patient AI Comms
Meizlish brings deep expertise in healthcare innovation and leadership, with a track record of building growth-stage companies and driving transformative partnerships. He co-founded and served as president of Lumere, a clinical evidence and analytics company acquired by Global Healthcare Exchange (GHX), where he later served as Senior Vice President of Strategy and Corporate Development. Most recently, he was CEO of Prendio-BioProcure, a leading cloud-based eProcurement platform for the life sciences industry.
“With the talent and innovation already in place at Cardiosense, we can transform how cardiac disease is managed. Our team has created a technical capability that has never existed before: the ability to accurately predict volumes and pressures within the heart, non-invasively,” said Eric Meizlish, CEO, Cardiosense. “Our next chapter is about scaling a platform that delivers these key measures to patients and providers to improve care and change the trajectory of heart disease. I look forward to working with the team to accelerate the impact for patients, providers, and partners at a moment when the industry is ready to embrace AI and digital solutions for heart health.”
Source: Businesswire